http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160026034-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ede47b877b6df9c8d0c494cd66f45ae8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2014-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a75259c00f8aab1ecbc0fdf39b6b9db3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5698d5885ac6e761977aa7b706fde66e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21d95c039551d441a11b0e7c351f1a3b |
| publicationDate | 2016-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20160026034-A |
| titleOfInvention | Pharmaceutical composition for preventing or treating cancers comprising dendritic cells with Foxp3 gene silenced |
| abstract | The present invention relates to a pharmaceutical composition for preventing or curing a cancer, and more specifically, to a pharmaceutical composition including a dendritic cell in which a Foxp3 gene is knocked down. The pharmaceutical composition according to the present invention includes a dendritic cell, in which the Foxp3 gene is knocked down or knocked out, or protein activity of F-oxp3 protein is inhibited, as the active component. When the Foxp3 gene is knocked down or knocked out or the activity of Foxp3 protein is inhibited, the number of CD11b/CD11c/CD103 triple positive dendritic cells which contribute to the immune control tremendously decreases, while antigen uptake and T-cell stimulation surface molecules greatly increase. Also, the activity of antigen-specific cytotoxic T lymphocytes (CTLs) which can attack cancer cells increase, thereby preventing, alleviating or curing cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110573181-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019177200-A1 |
| priorityDate | 2014-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 351.